Endocrine

Metabolic syndrome: diagnosis and management

Clinical Overview and When to Suspect Metabolic Syndrome

— Waist circumference ≥102 cm (M) / ≥88 cm (F); lower thresholds (≥90/≥80 cm) for South/East Asian, Hispanic populations

— Triglycerides ≥150 mg/dL (or on fibrate/niacin)

— HDL <40 mg/dL (M) / <50 mg/dL (F) (or on therapy)

— Blood pressure ≥130/85 mmHg (or on antihypertensive)

— Fasting glucose ≥100 mg/dL (or on glucose-lowering therapy)

— Adult presenting for routine physical with central obesity, acanthosis nigricans, or skin tags

— Patient on antihypertensive or statin who has not been screened for glucose

— Polycystic ovary syndrome, NAFLD detected on imaging, gestational diabetes history

— Severe psychiatric illness on second-generation antipsychotics (olanzapine, clozapine)

— HIV patients on older antiretrovirals (lipodystrophy pattern)

— 2× risk of cardiovascular disease and 5× risk of progressing to type 2 diabetes

— Independently predicts NAFLD/NASH, obstructive sleep apnea, chronic kidney disease, certain cancers (colon, breast, endometrial), and all-cause mortality

Definition (NCEP ATP III / AHA-NHLBI harmonized criteria): ≥3 of 5 criteria

Pathophysiologic core: visceral adiposity → insulin resistance → atherogenic dyslipidemia, endothelial dysfunction, low-grade inflammation, prothrombotic state

Epidemiology: ~one-third of US adults; prevalence rises sharply with age, postmenopausal status, South Asian ancestry, and lower socioeconomic status

When to suspect in clinic:

Why it matters for Step 3:

Board pearl: Metabolic syndrome is a clinical construct, not a disease — it identifies a patient who needs aggressive lifestyle intervention and individual risk-factor treatment, not a single "syndrome-directed" drug. The Step 3 question that asks "best next step" almost always rewards intensive lifestyle modification with 7% weight loss target and 150 min/week moderate activity before pharmacotherapy in the asymptomatic patient without established ASCVD or diabetes.

Presentation Patterns and Key History

— Fatigue, daytime somnolence, loud snoring, witnessed apneas → screen for OSA (STOP-BANG)

— Polyuria, polydipsia, blurred vision → check A1c/fasting glucose

— Erectile dysfunction in men <60 — often a sentinel for endothelial dysfunction and incident CAD within 3–5 years

— Oligomenorrhea, hirsutism, infertility in women → PCOS workup

— RUQ discomfort, incidental "fatty liver" on imaging → NAFLD evaluation

— Weight trajectory (pregnancy weight retention, weight gain on new psychotropic, post-smoking-cessation gain)

— Dietary pattern: sugar-sweetened beverages, ultra-processed food frequency, alcohol (calories + triglyceride driver)

— Physical activity: minutes/week of moderate-vigorous activity, sedentary time

— Sleep duration <6 hr and shift work — independent risk factors for insulin resistance

— Tobacco (worsens insulin resistance, lowers HDL)

— Family history of premature ASCVD (<55 M / <65 F), T2DM, dyslipidemia

— OB history: gestational diabetes, preeclampsia, macrosomic infant, PCOS — all confer lifetime cardiometabolic risk

— Medications: atypical antipsychotics, glucocorticoids, protease inhibitors, β-blockers, thiazides at high dose

— Food insecurity, neighborhood walkability, access to primary care, health literacy — directly modify achievable lifestyle targets

Typical vignette: 45–65-year-old presenting for annual exam, employment physical, or unrelated complaint (knee pain, fatigue, erectile dysfunction, snoring). The patient feels well — that is the trap.

Symptom clusters that should prompt screening:

Targeted history checklist:

Social determinants (Step 3 favorite):

Key distinction: Metabolic syndrome and prediabetes overlap but are not identical — a patient can meet metabolic syndrome criteria with a normal A1c (impaired fasting glucose alone suffices), and conversely a lean patient with A1c 6.0% has prediabetes without metabolic syndrome. Both warrant intensive lifestyle intervention, but only the latter automatically triggers consideration of metformin per ADA when A1c 5.7–6.4% plus BMI ≥35, age <60, or prior GDM.

Physical Exam Findings (and Hemodynamic Assessment when relevant)

— BP after 5 min seated rest, feet flat, arm at heart level, appropriate cuff size; repeat in contralateral arm; ≥130/85 mmHg meets criterion

— Out-of-office confirmation (home BP or ABPM) before labeling hypertension — Step 3 emphasizes avoiding white-coat overdiagnosis

— Resting HR (tachycardia suggests sympathetic overdrive, deconditioning, or undertreated OSA)

— Waist circumference at the iliac crest, end of normal expiration — more predictive than BMI for cardiometabolic risk

— BMI ≥30 kg/m² (≥27.5 for Asian populations) — but normal-weight central obesity ("TOFI") still qualifies

— Neck circumference >17 in (M) / >16 in (F) correlates with OSA risk

— Acanthosis nigricans — velvety hyperpigmentation at neck, axillae, knuckles

— Multiple skin tags (acrochordons), particularly on neck

— Hirsutism, acne, androgenetic alopecia in women (PCOS overlap)

— Xanthelasma, tendinous xanthomas (consider familial hyperlipidemia)

— Eruptive xanthomas on extensor surfaces → triglycerides often >1000 mg/dL, pancreatitis risk

— S4 gallop (LV stiffness from hypertensive heart disease)

— Carotid or femoral bruits (subclinical atherosclerosis)

— Diminished pedal pulses, ABI <0.9 → PAD

— Crowded oropharynx, Mallampati III–IV, retrognathia → OSA

— Hepatomegaly without tenderness — NAFLD

— Striae, buffalo hump, moon facies → screen for Cushing syndrome (secondary cause)

— Reduced vibratory and monofilament sensation if undiagnosed diabetes

— Dependent edema (heart failure, OSA-related cor pulmonale)

Vital signs first — measured correctly:

Anthropometrics:

Skin and integument clues to insulin resistance:

Cardiovascular and pulmonary:

Abdomen:

Lower extremities:

Step 3 management: A patient with BP 138/88, waist 104 cm, and acanthosis nigricans on a routine visit should leave with home BP monitoring instructions, fasting lipid panel + A1c + LFTs ordered, and a scheduled return visit in 2–4 weeks — not an immediate prescription. Document shared decision-making about lifestyle goals before pharmacotherapy.

Diagnostic Workup — Initial Labs / Imaging / ECG / Biomarkers

— Lipid panel: total cholesterol, LDL-C (calculated or direct), HDL-C, triglycerides; non-HDL = TC − HDL useful when TG >200

— Hemoglobin A1c AND fasting plasma glucose — capture both prediabetes phenotypes

— Basic metabolic panel: creatinine with eGFR, electrolytes (baseline before ACEi/ARB/diuretic)

— ALT/AST — NAFLD screen; calculate FIB-4 ((age × AST)/(platelets × √ALT)) — score >1.3 (or >2.0 if age >65) prompts hepatology evaluation per AASLD 2023

— Urine albumin-to-creatinine ratio (UACR) — microalbuminuria ≥30 mg/g signals endothelial injury, CKD risk, and supports earlier RAAS blockade

— TSH (rule out hypothyroid contribution to dyslipidemia and weight gain)

— Uric acid (hyperuricemia tracks with insulin resistance, predicts gout)

— hs-CRP if borderline ASCVD risk and considering statin (a "risk enhancer" per 2018 ACC/AHA cholesterol guideline)

— Lipoprotein(a) once in lifetime per 2022 NLA consensus — particularly with family history of premature ASCVD

— Apolipoprotein B for residual risk assessment if TG >200 or diabetes

— Free testosterone/SHBG, LH, FSH in women with oligomenorrhea (PCOS)

— 1 mg overnight dexamethasone suppression test if Cushingoid features or refractory hypertension + obesity

— Aldosterone-renin ratio if hypertension with hypokalemia or resistant HTN

— 12-lead ECG at baseline — LVH (Sokolow-Lyon, Cornell), prior silent MI, conduction disease

— Right upper quadrant ultrasound if ALT elevated — confirms hepatic steatosis

— Coronary artery calcium (CAC) score in intermediate-risk adults (10-yr ASCVD 5–<20%) to refine statin decision; CAC = 0 may justify deferral, CAC ≥100 or ≥75th percentile justifies initiation

Core laboratory panel (fasting preferred for first assessment):

When to add:

Imaging and ECG:

Board pearl: A non-fasting lipid panel is acceptable for screening per 2018 ACC/AHA — but if triglycerides >400 mg/dL non-fasting, repeat fasting before calculating LDL with the Friedewald equation, which becomes inaccurate at high TG.

Diagnostic Workup — Advanced or Confirmatory Studies

— Young patient (<35), lean body habitus with severe dyslipidemia → genetic dyslipidemia panel; consider familial hypercholesterolemia (LDL >190 untreated)

— Resistant hypertension (≥3 drugs including diuretic, BP uncontrolled) → renal artery duplex, plasma metanephrines, aldosterone-renin ratio, polysomnography

— Truncal obesity + proximal weakness + purple striae → 24-hr urine free cortisol or late-night salivary cortisol after positive overnight DST

— Hypothyroidism, acromegaly (IGF-1), and hypogonadism workups when clinical clues present

— Step 1: FIB-4 risk stratify

— Step 2 (FIB-4 indeterminate or high): vibration-controlled transient elastography (FibroScan) or ELF blood test

— Step 3: hepatology referral for possible biopsy if advanced fibrosis (F3–F4) suspected

— Rule out competing etiologies: hepatitis B/C serology, ferritin/transferrin saturation, ceruloplasmin if <40 yo, autoimmune panel, alcohol history

— STOP-BANG ≥3 or Epworth ≥10 → home sleep apnea test (HSAT) in uncomplicated patients

— In-lab polysomnography if heart failure, suspected central apnea, neuromuscular disease, severe comorbidities, or HSAT non-diagnostic

— AHI ≥5 with symptoms or ≥15 regardless of symptoms = diagnostic

— Pooled Cohort Equation for 10-year ASCVD risk in adults 40–75; recalculate annually with updated values

— Risk enhancers: family history premature ASCVD, persistent LDL ≥160, CKD, metabolic syndrome itself, chronic inflammatory disease, premature menopause, preeclampsia history, South Asian ancestry, persistent TG ≥175, elevated Lp(a), hs-CRP ≥2, ABI <0.9

Secondary cause workup — when phenotype seems "atypical":

NAFLD/MASLD staging (now preferred terminology — metabolic dysfunction-associated steatotic liver disease):

OSA confirmation:

Cardiovascular risk refinement:

Step 3 management: A 52-year-old man with metabolic syndrome and 10-yr ASCVD risk of 8.5% (intermediate) is the classic CAC scoring candidate — a score of 0 supports deferring statin and rechecking in 5–10 years; a score >100 mandates moderate-to-high intensity statin. Document the shared decision in the chart — Step 3 loves the "what did you discuss with the patient" stem.

Risk Stratification or First-Line Management Logic

— Confirm diagnosis with repeat measurements and out-of-office BP

— Quantify global ASCVD risk and diabetes risk separately

— Identify and treat secondary causes if present (OSA, Cushing, hypothyroid, drug-induced)

— Set individualized targets and start structured lifestyle intervention before adding multiple medications

— 7–10% weight loss over 6 months — Diabetes Prevention Program showed 58% reduction in progression to T2DM, superior to metformin (31%)

— Mediterranean or DASH dietary pattern: vegetables, fruits, whole grains, legumes, nuts, olive oil, fish; limit ultra-processed foods, refined carbs, sugar-sweetened beverages

— Physical activity: ≥150 min/week moderate-intensity aerobic + 2 sessions resistance training

— Sleep ≥7 hours; treat OSA if diagnosed

— Tobacco cessation with combined pharmacotherapy + behavioral support

— Alcohol ≤1 drink/day women, ≤2 men; eliminate if hypertriglyceridemia

— Referral to registered dietitian and intensive behavioral counseling (USPSTF Grade B for adults with CVD risk factors — covered without cost-sharing under ACA)

— BP ≥130/80 → lifestyle ± pharmacotherapy per ACC/AHA 2017 (if 10-yr ASCVD ≥10% or comorbidity); otherwise ≥140/90 for low-risk

— LDL — statin if clinical ASCVD, LDL ≥190, diabetes age 40–75, or 10-yr ASCVD ≥7.5% (consider) / ≥20% (definite)

— A1c 5.7–6.4% with BMI ≥35 or age <60 or prior GDM → consider metformin

— TG ≥500 mg/dL → fibrate/icosapent ethyl to prevent pancreatitis (before LDL focus)

Hierarchy of intervention (first 90 days):

Lifestyle prescription (the cornerstone — every patient):

Treatment thresholds for individual components:

CCS pearl: On CCS, in an otherwise asymptomatic patient newly diagnosed with metabolic syndrome, the high-yield order set is: dietitian referral, exercise counseling, tobacco cessation counseling, home BP monitor, follow-up in 4 weeks — then advance the clock. Premature pharmacotherapy without documenting lifestyle counseling loses points.

Pharmacotherapy — First-Line Drug Regimen

— First-line: ACE inhibitor or ARB, thiazide-like diuretic (chlorthalidone preferred over HCTZ), or dihydropyridine CCB (amlodipine)

— In metabolic syndrome with microalbuminuria or diabetes: ACEi/ARB first for renal protection

— Avoid high-dose thiazides and non-vasodilating β-blockers as monotherapy — worsen insulin resistance and dyslipidemia

— Combination therapy if BP >20/10 above goal at outset

— Moderate-intensity statin (atorvastatin 10–20, rosuvastatin 5–10) for primary prevention with intermediate risk

— High-intensity statin (atorvastatin 40–80, rosuvastatin 20–40) for ASCVD, LDL ≥190, diabetes with risk enhancers, or 10-yr risk ≥20%

— Add ezetimibe if LDL not at goal (<70 in very high risk, <100 in others) after maximally tolerated statin

— PCSK9 inhibitor (evolocumab, alirocumab) for very high-risk ASCVD or familial hypercholesterolemia not at goal

— Icosapent ethyl 2 g BID if TG 135–499 on statin with ASCVD or diabetes + risk factors (REDUCE-IT)

— Fibrate (fenofibrate) if TG ≥500 to prevent pancreatitis

— Metformin for prediabetes per ADA when A1c 5.7–6.4% plus BMI ≥35, age <60, or prior GDM

— If diabetes develops: metformin first, then add GLP-1 RA (semaglutide, liraglutide, tirzepatide) or SGLT2 inhibitor (empagliflozin, dapagliflozin) — both reduce MACE and offer weight loss

— GLP-1 RA preferred when obesity dominates; SGLT2i preferred with HF or CKD

— Semaglutide 2.4 mg weekly or tirzepatide — 15–22% weight loss

— Phentermine-topiramate, naltrexone-bupropion as alternatives

— Avoid in pregnancy; counsel on GI side effects, pancreatitis risk, gallstones

Hypertension (BP ≥130/80 in patient with ≥10% ASCVD risk, diabetes, CKD, or established CVD):

Dyslipidemia:

Dysglycemia:

Obesity pharmacotherapy (BMI ≥30, or ≥27 with comorbidity, inadequate response to lifestyle):

Board pearl: Aspirin is NOT routinely indicated for primary prevention in metabolic syndrome — 2019 ACC/AHA and USPSTF 2022 restrict it to selected adults 40–59 with ≥10% ASCVD risk and low bleeding risk via shared decision-making; avoid in adults ≥60 for primary prevention.

Procedures / Revascularization / Invasive Management (or expanded pharmacology if non-procedural)

— BMI ≥35 regardless of comorbidities

— BMI 30–34.9 with metabolic disease (T2DM particularly), failed nonsurgical management

— Asian populations: thresholds lowered by ~2.5 kg/m²

— Procedures: sleeve gastrectomy (most common, restrictive), Roux-en-Y gastric bypass (restrictive + malabsorptive, best for T2DM remission and severe GERD), duodenal switch / SADI (most weight loss, highest nutrient deficiency risk), adjustable gastric band (rarely used)

— T2DM remission 30–60% at 5 years (highest with RYGB and DS); improved BP, lipids, OSA, NAFLD

— STAMPEDE, SOS trials: surgery superior to medical therapy for sustained weight loss and metabolic control

— Mortality reduction ~30% over 10 years vs matched controls

— Multidisciplinary team: surgery, nutrition, behavioral health, endocrinology

— Screen and treat OSA; H. pylori test/treat; nutritional baseline (B12, iron, vitamin D, thiamine); pregnancy counseling — avoid pregnancy 12–18 months post-op

— Smoking cessation ≥6 weeks pre-op

— Psychosocial assessment to identify uncontrolled eating disorders, untreated substance use

— Lifelong multivitamin, calcium citrate 1200–1500 mg/day, vitamin D, B12, iron (menstruating women)

— Monitor B12, folate, iron, vitamin D, PTH, zinc, copper annually

— Dumping syndrome after RYGB — avoid simple sugars

— Internal hernia risk after RYGB — any post-op patient with abdominal pain needs CT and surgical eval

— Reassess and deprescribe antihypertensives, insulin, sulfonylureas to prevent hypoglycemia and hypotension

— Intragastric balloon, endoscopic sleeve gastroplasty — bridge options for BMI 30–40

Metabolic syndrome is non-procedural, but bariatric/metabolic surgery and device therapy are increasingly board-relevant.

Metabolic (bariatric) surgery — ASMBS/IFSO 2022 indications:

Outcomes to know:

Pre-op evaluation (CCS-style order set):

Post-op management essentials:

Endoscopic and device therapies:

CCS pearl: Post-bariatric patient on metformin + glipizide + 40 units insulin should have sulfonylurea and insulin stopped or sharply reduced on day of surgery, with glucose monitored Q6h. Failure to deprescribe is a classic Step 3 patient-safety error.

Special Populations — Elderly and Renal/Hepatic Impairment

— Waist circumference and central obesity remain predictive, but BMI alone is misleading (sarcopenic obesity)

— Goal BP per ACC/AHA: <130/80 if community-dwelling, ambulatory, low fall risk; relax to <140/90 in frail elderly

— Avoid orthostatic hypotension — measure standing BP, deprescribe culprit agents

— Statins: continue secondary prevention indefinitely; for primary prevention in adults >75 with no ASCVD, individualize (USPSTF 2022: insufficient evidence; ACC/AHA permits shared decision-making with CAC scoring)

— Diabetes A1c target: 7.0–7.5% healthy; 7.5–8.0% moderate comorbidity; <8.5% frail/limited life expectancy (ADA)

— Avoid sulfonylureas and basal-bolus insulin when possible — hypoglycemia risk; favor metformin, GLP-1 RA, SGLT2i (with renal dose adjustment)

— Exercise prescription must include resistance and balance training to prevent sarcopenia and falls

— Metformin safe to eGFR ≥30; reduce dose at 30–45; stop if eGFR <30

— SGLT2 inhibitors initiate down to eGFR ≥20 for renal/cardiac protection per KDIGO 2022 (continue once started until dialysis)

— GLP-1 RAs safe across CKD spectrum; semaglutide and dulaglutide preferred

— Avoid NSAIDs; cautious thiazide use (less effective <eGFR 30 — switch to loop)

— ACEi/ARB: monitor K+ and creatinine 1–2 weeks after start/dose change; acceptable to continue with up to 30% creatinine rise

— Statins: atorvastatin no dose adjustment; rosuvastatin and pravastatin require renal dosing

— Statins are safe and recommended in compensated NAFLD/cirrhosis (Child-Pugh A) — reduce ASCVD events

— Avoid statins in decompensated cirrhosis (Child-Pugh C)

— Pioglitazone and resmetirom (FDA-approved 2024 for MASH with F2–F3 fibrosis) are MASH-targeted therapies

— GLP-1 RAs improve hepatic steatosis; semaglutide has MASH evidence

— Avoid metformin in acute liver failure or active alcohol use disorder (lactic acidosis risk)

Older adults (≥65–75):

Chronic kidney disease:

Hepatic impairment / NAFLD-cirrhosis:

Key distinction: In a 78-year-old frail patient with metabolic syndrome and A1c 7.8%, the correct answer is usually to liberalize the A1c goal and deprescribe, not intensify therapy. Step 3 rewards recognition that hypoglycemia in the elderly kills faster than hyperglycemia.

Special Populations — Pregnancy, Pediatrics, or Other Demographic Subgroups

— Preconception counseling for women with metabolic syndrome: optimize BMI, BP, glucose, lipids before conception

— Stop statins, ACEi/ARB, SGLT2i, GLP-1 RA before conception (statins now FDA category change 2021 — may be continued in select very-high-risk women per shared decision-making, but conservative practice is discontinuation)

— Methyldopa, labetalol, nifedipine are pregnancy-compatible antihypertensives; goal BP <140/90 (CHAP trial supports treating mild chronic HTN in pregnancy)

— Insulin and metformin are options for gestational diabetes; insulin preferred for type 2

— Screen for gestational diabetes at 24–28 weeks (75-g 2-hr OGTT or 50-g 1-hr screen → 100-g 3-hr); early screening at first visit if BMI ≥30, prior GDM, or strong family history

— Postpartum: 75-g 2-hr OGTT at 4–12 weeks for GDM patients; lifetime ASCVD risk discussion — GDM, preeclampsia, preterm delivery are sex-specific ASCVD risk enhancers

— Breastfeeding reduces maternal T2DM and CVD risk — encourage

— IDEFICS/IDF pediatric criteria: not diagnosed <10 years; ages 10–16 use modified adult-style criteria with age-specific cutoffs; ≥16 use adult criteria

— Screen BP annually starting age 3, lipids once age 9–11 and again 17–21 (NHLBI), A1c if BMI ≥85th percentile + risk factors

— First-line: family-based lifestyle intervention; metformin approved ≥10 yo; liraglutide ≥10 yo, semaglutide ≥12 yo, phentermine ≥16 yo for obesity

— Bariatric surgery considered ≥13 yo with severe obesity per AAP 2023 guideline

— Treat OSA aggressively — adenotonsillectomy if indicated

— South Asians: lower BMI/waist thresholds; higher visceral fat at any BMI; statin and lifestyle thresholds lowered

— Severe mental illness on antipsychotics: monitor weight, lipids, glucose at baseline, 12 weeks, then annually (APA monitoring guideline); consider switching to lower-risk agent (aripiprazole, ziprasidone)

— HIV: integrase inhibitors and TAF cause weight gain; monitor metabolic parameters

Pregnancy and preconception:

Pediatric and adolescent metabolic syndrome:

Other subgroups:

Board pearl: A woman with prior gestational diabetes has a 50–70% lifetime risk of T2DM — annual A1c or fasting glucose for life is the Step 3 answer.

Complications and Adverse Outcomes

— Coronary artery disease, MI, stroke (2× risk vs no metabolic syndrome)

— Heart failure with preserved ejection fraction (HFpEF) — strong association with obesity, hypertension, diabetes

— Atrial fibrillation — obesity and OSA are major modifiable drivers

— Peripheral arterial disease

— Sudden cardiac death

— Progression to type 2 diabetes (5× risk) with downstream microvascular complications (retinopathy, nephropathy, neuropathy)

— Diabetic ketoacidosis or hyperosmolar hyperglycemic state at presentation

— Hypogonadism in men (low testosterone tracks with visceral adiposity)

— PCOS-associated infertility, endometrial hyperplasia

— NAFLD → NASH → cirrhosis → hepatocellular carcinoma (now leading transplant indication)

— Cholelithiasis and acute pancreatitis (especially with TG >1000)

— Chronic kidney disease, often non-diabetic at first (obesity-related glomerulopathy with FSGS pattern)

— Nephrolithiasis (uric acid stones)

— OSA → pulmonary hypertension, right heart failure

— Obesity hypoventilation syndrome (BMI ≥30, awake PaCO₂ ≥45)

— Asthma exacerbation

— Increased risk of colorectal, breast (postmenopausal), endometrial, pancreatic, hepatocellular, renal, esophageal adenocarcinoma

— Worse outcomes after cancer diagnosis

— Osteoarthritis (weight-bearing joints), gout, low back pain

— Vascular cognitive impairment and increased Alzheimer dementia risk

— Depression — bidirectional relationship with obesity and diabetes

— Erectile dysfunction (often heralds CAD by 3–5 years)

— Subfertility in both sexes

Cardiovascular:

Endocrine/metabolic:

Hepatobiliary:

Renal:

Pulmonary:

Oncologic:

Musculoskeletal:

Cognitive/psychiatric:

Reproductive/sexual:

Step 3 management: A patient with new-onset AF, BMI 38, snoring, and BP 145/92 needs simultaneous AF rate control + anticoagulation per CHA₂DS₂-VASc + OSA evaluation + weight loss program. Treating only the rhythm misses that 10% weight loss can produce AF burden reduction comparable to ablation in selected patients (LEGACY trial).

When to Escalate Care — ICU, Consult, or Inpatient Triage

— Hypertensive emergency (BP >180/120 with end-organ damage: chest pain, dyspnea, focal neuro deficit, AKI, papilledema) → ED for IV antihypertensives in monitored setting

— DKA or HHS: ketones, glucose >250–600, altered mental status, AG metabolic acidosis → ED

— Acute coronary syndrome symptoms → ED, do not delay for outpatient workup

— Acute pancreatitis suspicion with severe hypertriglyceridemia (>1000) → ED; may require plasmapheresis or insulin infusion

— Decompensated heart failure (orthopnea, weight gain, hypoxia) → ED

— Endocrinology: type 1 vs type 2 ambiguity, severe insulin resistance (>1 U/kg/day), refractory dyslipidemia, secondary HTN workup positive, suspected Cushing/pheochromocytoma

— Cardiology: known ASCVD, abnormal stress test, CAC ≥300 or ≥75th percentile, HFpEF management

— Hepatology: FIB-4 >2.67, elastography ≥8 kPa, suspected cirrhosis, MASH with F2+ fibrosis

— Nephrology: eGFR <30, UACR >300, rapidly declining function

— Sleep medicine: complex OSA, central apnea, CPAP failure

— Bariatric surgery: BMI ≥35 or ≥30 with T2DM, failed medical management

— Genetics: familial hypercholesterolemia (LDL ≥190 with family history)

— Behavioral health: binge eating disorder, depression, alcohol use disorder

— Newly recognized A1c ≥6.5% during admission → initiate workup, schedule outpatient follow-up within 1–2 weeks

— BP repeatedly elevated → confirm with proper technique, defer non-urgent initiation to outpatient unless end-organ damage; avoid "stat" antihypertensives for asymptomatic elevated BP (a Choosing Wisely target)

Emergency department / inpatient triage from clinic:

Subspecialty referrals from the medical home:

Inpatient consults during admission for unrelated reasons:

CCS pearl: On a CCS case, a patient with metabolic syndrome admitted for chest pain who is "ruled out" should be discharged with statin, BP medication if indicated, smoking cessation counseling, cardiac rehab referral, and primary care follow-up in 1–2 weeks — not just discharged on aspirin. Forgetting secondary prevention bundles at discharge is the most common scoring miss.

Key Differentials — Same-Category Causes

— Truncal obesity, hypertension, hyperglycemia, dyslipidemia mimic metabolic syndrome

— Clues: proximal muscle weakness, wide violaceous striae, easy bruising, moon facies, supraclavicular/dorsocervical fat pads, hypokalemia

— Screen: 1 mg overnight dexamethasone suppression test, 24-hr urine free cortisol, late-night salivary cortisol — need 2 abnormal tests

— Pseudo-Cushing from severe obesity, depression, alcohol use disorder can confound — dexamethasone-CRH test or repeat over time

— Weight gain, dyslipidemia (elevated LDL), HTN, fatigue

— TSH is part of any new metabolic workup; treat with levothyroxine and reassess lipids

— Insulin resistance, HTN, sleep apnea, cardiomyopathy

— Clues: enlarging hands/feet/jaw, macroglossia, skin tags, hyperhidrosis

— Screen: IGF-1; confirm with oral glucose tolerance test (failure to suppress GH)

— Strongly overlaps with metabolic syndrome in young women; insulin resistance is the shared mechanism

— Rotterdam criteria (2 of 3): oligo/anovulation, hyperandrogenism, polycystic ovaries on US

— Manage hyperandrogenism (OCPs, spironolactone), insulin resistance (metformin, lifestyle, GLP-1 RA), fertility (letrozole)

— Resistant HTN, hypokalemia, metabolic alkalosis, often with central obesity

— Screen: aldosterone-renin ratio; confirm with saline infusion or oral salt loading; localize with adrenal CT and AVS

— Underdiagnosed — consider in any HTN patient on 3+ agents

— Paroxysmal HTN, palpitations, headache, diaphoresis; can present with new diabetes

— Plasma free or 24-hr urine metanephrines

— Heterozygous familial hypercholesterolemia (LDL ≥190, tendon xanthomas, family history premature ASCVD) — needs high-intensity statin + ezetimibe ± PCSK9i; cascade screen first-degree relatives

— Familial combined hyperlipidemia, dysbetalipoproteinemia (type III, broad β-band)

— Lean adult with hyperglycemia, ketosis-prone — check GAD-65, IA-2 antibodies, C-peptide

Endocrine/metabolic mimics or contributors that should be excluded:

Cushing syndrome:

Hypothyroidism:

Acromegaly:

Polycystic ovary syndrome:

Primary aldosteronism:

Pheochromocytoma:

Familial dyslipidemias:

Type 1 diabetes / LADA:

Key distinction: Metabolic syndrome does not have hypokalemia as a feature — if your "metabolic syndrome" patient has K⁺ <3.5 on no diuretic, stop and screen for primary aldosteronism before adding more BP medications.

Key Differentials — Other-Category Causes

— Second-generation antipsychotics: olanzapine and clozapine are worst; aripiprazole and ziprasidone are weight/metabolically neutral — APA recommends baseline and periodic weight, lipids, glucose monitoring

— Glucocorticoids: long-term prednisone causes truncal weight gain, IGT, dyslipidemia, HTN — minimize dose, add bone protection

— Antiretrovirals: older PIs (lopinavir/ritonavir) and integrase inhibitors (dolutegravir, bictegravir) → weight gain; TAF more than TDF

— β-blockers (non-vasodilating) and high-dose thiazides: worsen glucose, lipids — avoid as first-line in metabolic syndrome

— Tacrolimus, cyclosporine: post-transplant diabetes, HTN, dyslipidemia

— Valproate, mirtazapine, gabapentin/pregabalin: weight gain

— Lipodystrophies (congenital generalized, familial partial): severe insulin resistance, hypertriglyceridemia, NAFLD with paradoxical low subcutaneous fat — leptin replacement (metreleptin) available

— Prader-Willi, Bardet-Biedl — pediatric obesity syndromes

— MODY (maturity-onset diabetes of the young) — atypical diabetes presentations

— Rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus, AS — chronic inflammation accelerates atherosclerosis; included as ASCVD risk enhancers

— Aggressive cardiometabolic risk reduction warranted even at "intermediate" calculated risk

— HIV itself and antiretroviral therapy independently increase ASCVD risk; REPRIEVE trial supports statin for primary prevention in HIV adults 40–75 with low-moderate ASCVD risk

— Nephrotic syndrome: severe dyslipidemia, edema, proteinuria — different mechanism, treat underlying nephropathy

— Cholestatic liver disease (PBC, biliary obstruction): elevated cholesterol from lipoprotein-X; treat underlying disease

— Can cause secondary HTN, pulmonary HTN, polycythemia, glucose intolerance

— Treating OSA improves BP and glucose

— Non-adherence, white-coat effect, improper cuff/technique, suboptimal regimen

— Verify with ambulatory BP monitoring and pharmacy fill data before adding the 4th drug

Drug-induced metabolic phenotypes:

Genetic/syndromic causes of central adiposity and metabolic abnormalities:

Inflammatory and rheumatologic:

HIV and chronic infections:

Renal and hepatic mimics:

OSA and obesity hypoventilation:

Pseudo-resistant hypertension:

Board pearl: A psychiatric patient newly started on olanzapine gaining 8 kg in 3 months with new prediabetes — Step 3 answer is to discuss switching to a metabolically neutral antipsychotic with psychiatry, not to add metformin alone. Address the driver.

Secondary Prevention / Discharge Medications / Long-Term Plan

— High-intensity statin (atorvastatin 80 or rosuvastatin 40); add ezetimibe ± PCSK9i if LDL >70 (target <55 in very-high-risk per ACC)

— Antiplatelet: aspirin 81 mg indefinitely; DAPT (ASA + P2Y12) for 12 months post-ACS, then aspirin alone (or P2Y12 alone in some regimens)

— ACE inhibitor or ARB for all post-MI with EF <40%, HTN, diabetes, CKD

— β-blocker post-MI (carvedilol, metoprolol succinate, bisoprolol if reduced EF)

— SGLT2 inhibitor if HFrEF, HFpEF, CKD, or T2DM with ASCVD — empagliflozin or dapagliflozin

— GLP-1 RA if T2DM with ASCVD or high risk — semaglutide, liraglutide, dulaglutide

— Mineralocorticoid antagonist (spironolactone, eplerenone) in HFrEF EF ≤35% post-MI

— Aldosterone receptor antagonist for resistant HTN

— Influenza, COVID-19, pneumococcal, RSV (≥60), Tdap, zoster (≥50), hepatitis B vaccinations

— Cardiac rehabilitation referral (Class I, 36 sessions) — improves mortality, often underutilized

— Smoking cessation with varenicline or combination NRT + bupropion + counseling

— Lifestyle prescription documented at every visit

— Statin if ASCVD risk ≥7.5–20% per shared decision-making; ≥20% definite

— BP control to <130/80 if ≥10% ASCVD risk or diabetes/CKD

— Aspirin only in select 40–59 yo with ≥10% risk and low bleed risk

— Cancer screening per USPSTF (colon ≥45, breast, cervical, lung if eligible)

— Annual eye exam and foot exam once diabetes diagnosed

— Annual UACR and eGFR if diabetes, HTN, or CKD

— After 5–10% weight loss, reassess and down-titrate antihypertensives, sulfonylureas, insulin to prevent hypotension and hypoglycemia

— Document the deprescribing rationale

For the post-ACS / post-stroke patient with metabolic syndrome (secondary prevention bundle):

For the primary prevention patient with metabolic syndrome:

Deprescribing checkpoints:

Step 3 management: The post-discharge medication reconciliation after an MI in a metabolic syndrome patient should include ASA + P2Y12 + high-intensity statin + ACEi + β-blocker + (SGLT2i or GLP-1 RA if diabetes/HF) + cardiac rehab referral. Missing any of these is a documented quality gap (CMS, NCQA).

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— Every 2–4 weeks during medication titration (BP, glucose, statin tolerance)

— Home BP log review at each visit; ambulatory BP monitoring if discordance

— Weight, waist circumference at each visit; reinforce 7–10% weight loss target

— BP, weight, waist

— A1c every 3 months until at goal then every 6 months (or fasting glucose if non-diabetic)

— Lipid panel 4–12 weeks after statin start, then annually

— LFTs at baseline and only if symptoms (routine surveillance no longer required on stable statin)

— BMP for ACEi/ARB/diuretic — within 2 weeks of start, then 6–12 months

— CK only if muscle symptoms — not routine

— UACR and eGFR annually in diabetes, HTN, CKD

— Dilated eye exam annually (or per ophthalmology in diabetes)

— Comprehensive foot exam annually in diabetes; daily self-exam education

— DEXA scan if risk factors

— Vaccinations updated annually

— NAFLD reassessment with FIB-4 every 1–3 years

— Sleep symptoms review annually; repeat polysomnography if symptoms recur on CPAP

— Mental health screening (PHQ-2/9, GAD-7) annually — depression and anxiety drive nonadherence

— Post-MI, post-PCI, post-CABG, stable angina, HFrEF, post-valve surgery — Class I, mortality benefit, underused

— 36 supervised sessions over 12 weeks typical; covered by Medicare and most insurers

— Identify patient's readiness to change for each behavior (transtheoretical model)

— SMART goals (specific, measurable, achievable, relevant, time-bound)

— Address food access, cooking skills, neighborhood walkability — social determinants

— Connect to community resources: YMCA Diabetes Prevention Program (DPP) — CMS-covered for eligible Medicare beneficiaries

— Pharmacist medication therapy management for polypharmacy

Initial intensive phase (first 6 months):

Once stable (every 3–6 months):

Annual or per-condition surveillance:

Cardiac rehabilitation:

Counseling content (motivational interviewing framework):

Board pearl: CMS-covered DPP is a 12-month structured behavioral intervention available to Medicare beneficiaries with prediabetes — referring eligible patients is high-yield both clinically and on Step 3 stems about resource utilization.

Ethical, Legal, and Patient Safety Considerations

— Documented bias in clinical encounters reduces patient trust and follow-up

— Use person-first language ("patient with obesity," not "obese patient")

— Ensure clinic has appropriate equipment (large BP cuffs, weight-rated chairs and exam tables, gowns)

— Address concerns without focusing solely on weight — patients with obesity are underdiagnosed for unrelated conditions

— Statin for primary prevention is a classic shared decision-making conversation — discuss absolute risk reduction (NNT ~50–100 over 10 years for intermediate-risk primary prevention), side effects (myalgia ~5%, new-onset diabetes ~1 per 1000 patient-years), and patient preferences

— Bariatric surgery requires comprehensive informed consent: lifelong nutritional supplementation, pregnancy implications, possible weight regain, surgical and nutritional complications

— GLP-1 RAs in non-diabetic patients: discuss cost, indefinite duration (weight regain on discontinuation), GI side effects, possible pancreatitis/gallstone risk, contraindications (personal/family MTC or MEN2)

— Medication reconciliation at every transition (admission, discharge, post-procedure) — most common source of preventable adverse events

— Post-bariatric patients: deprescribe insulin, sulfonylureas, and antihypertensives at discharge to prevent hypoglycemia and orthostatic syncope

— Hospital discharge after MI: ensure 1–2 week PCP follow-up, cardiac rehab referral, pillbox/blister-pack if low health literacy, and teach-back confirmation

— Driving safety: a patient with uncontrolled hypoglycemia, severe OSA with daytime sleepiness, or new seizure may have driving restrictions — state laws vary; document counseling

— Commercial driver license (CDL) holders: BP, diabetes control, OSA screening required per DOT

— Metabolic syndrome disproportionately affects racial/ethnic minorities and lower-SES populations — address food insecurity (screen with Hunger Vital Sign), pharmacy cost barriers (use $4 generics, 90-day fills, patient assistance programs)

— Insurance coverage for GLP-1 RAs varies — document medical necessity and explore alternatives

— Sensitive disclosures (substance use, eating disorder, sexual dysfunction) should be obtained alone, not with family present

Weight stigma and bias:

Informed consent and shared decision-making:

Transitions of care — the highest-yield Step 3 safety topic:

Mandatory reporting and legal:

Health equity:

Confidentiality:

Step 3 management: A patient discharged after gastric bypass still on glipizide who returns with a syncopal hypoglycemic episode represents a failure of discharge medication reconciliation — the systems answer is to implement a pharmacist-led post-bariatric medication review protocol, not just to blame the prescriber.

High-Yield Associations and Rapid-Fire Clinical Facts

— ≥3 of 5 ATP III criteria; no single component is required

— Waist >102 cm (M) / >88 cm (F); Asian: >90/>80

— TG ≥150, HDL <40/<50, BP ≥130/85, FPG ≥100

— 2× ASCVD risk, 5× T2DM risk

— AF risk doubles with obesity and OSA

— Lifetime T2DM after GDM: 50–70%

— Metformin — first-line for T2DM and DPP-eligible prediabetes; B12 deficiency on long-term use (check at 4 years)

— GLP-1 RA: semaglutide and tirzepatide for weight + MACE; contraindicated in personal/family MTC or MEN2; pause before elective surgery (1 week per ASA 2023 guidance for non-emergent cases — controversial, evolving)

— SGLT2i: first-line in HF, CKD, T2DM with ASCVD; risks — euglycemic DKA (hold pre-op 3–4 days), genital mycotic infections, Fournier gangrene (rare), volume depletion

— Statin intolerance — rechallenge, switch, lower dose, or alternate-day dosing; muscle symptoms often non-statin in origin (SAMSON trial)

— Icosapent ethyl — only EPA-only formulation with CV outcomes benefit (REDUCE-IT); fish oil OTC mixed EPA/DHA does not have the same evidence

— Bempedoic acid — alternative for statin-intolerant; CLEAR Outcomes showed MACE reduction

— DPP — lifestyle > metformin for T2DM prevention

— LEGACY/SOS — weight loss for AF and overall outcomes

— STAMPEDE — bariatric surgery vs medical therapy for T2DM

— REDUCE-IT — icosapent ethyl for high TG + statin

— EMPA-REG, CANVAS, DAPA-HF, EMPEROR, FIDELIO/FIGARO — SGLT2i and finerenone

— STEP, SURMOUNT — semaglutide and tirzepatide for obesity

— SELECT — semaglutide reduces MACE in obesity without diabetes

— ADA: screen T2DM in adults ≥35 (or any BMI ≥25 with risk factor) every 3 years

— USPSTF: statin for primary prevention, ages 40–75 with ≥1 risk factor and ≥10% ASCVD risk (Grade B)

— USPSTF: behavioral counseling for adults with CVD risk (Grade B)

— USPSTF: intensive behavioral interventions for adults with BMI ≥30 (Grade B)

Diagnosis quick facts:

Risk magnitudes:

Drug pearls:

Trials worth knowing:

Screening rules:

Board pearl: "Patient with central obesity, hypertension, prediabetes, fatty liver, snoring" — the unifying diagnosis Step 3 wants is metabolic syndrome, and the unifying treatment is lifestyle intervention with 7–10% weight loss as the anchor.

Board Question Stem Patterns

— 48 yo with waist 108 cm, BP 134/86, TG 180, HDL 38, FPG 108

— Question: "What is the most appropriate next step?"

— Answer: Intensive lifestyle modification (diet, exercise, weight loss) — not immediate statin or metformin

— 55 yo, 10-yr ASCVD 8%, metabolic syndrome, hesitant about statin

— Answer: Coronary artery calcium scoring to refine risk and guide shared decision-making

— Patient 2 weeks s/p sleeve gastrectomy on glipizide, presents with sweating and confusion

— Answer: Discontinue sulfonylurea, manage acute hypoglycemia; broader lesson — medication reconciliation at discharge

— New diabetes, BP 142/90, started on HCTZ 50 + atenolol — A1c worsens

— Answer: Switch to ACEi or ARB ± dihydropyridine CCB; high-dose thiazide and non-vasodilating β-blocker worsen insulin resistance

— Postpartum patient with prior GDM, breastfeeding, BMI 31

— Answer: 75-g 2-hr OGTT at 4–12 weeks postpartum, then A1c or FPG every 1–3 years for life

— BP 156/96 on lisinopril + amlodipine + HCTZ, K⁺ 3.2

— Answer: Aldosterone-to-renin ratio to screen for primary aldosteronism

— ALT 70, BMI 34, T2DM, FIB-4 = 2.1

— Answer: Vibration-controlled transient elastography and hepatology referral if advanced fibrosis suggested

— New diffuse muscle aches on atorvastatin 40, CK normal

— Answer: Hold, rechallenge at lower dose or different statin; consider rosuvastatin alternate-day; add ezetimibe if needed

— TG 920, no symptoms

— Answer: Fibrate (fenofibrate) ± icosapent ethyl, dietary changes, alcohol cessation, glycemic control; statin alone insufficient

— 65 yo with metabolic syndrome, no ASCVD, asks about aspirin

— Answer: Do not start aspirin for primary prevention in adults ≥60 (USPSTF 2022)

Stem pattern 1 — The annual physical:

Stem pattern 2 — The shared decision-making CAC stem:

Stem pattern 3 — The post-bariatric hypoglycemia:

Stem pattern 4 — The wrong antihypertensive:

Stem pattern 5 — The GDM follow-up:

Stem pattern 6 — Resistant HTN with hypokalemia:

Stem pattern 7 — The NAFLD escalation:

Stem pattern 8 — Statin myalgia:

Stem pattern 9 — Hypertriglyceridemic pancreatitis prevention:

Stem pattern 10 — Primary prevention aspirin:

Key distinction: When a Step 3 stem presents a "well" patient with metabolic syndrome, the answer is almost never "start three drugs today" — it is identify, counsel, refer, and follow up systematically. When the stem presents established ASCVD or diabetes, the answer pivots to aggressive guideline-directed pharmacotherapy bundles.

One-Line Recap

Metabolic syndrome is a cluster of cardiometabolic risk factors — central obesity, atherogenic dyslipidemia, hypertension, and dysglycemia — that doubles cardiovascular risk and quintuples diabetes risk, and whose management centers on intensive lifestyle modification with 7–10% weight loss, individualized treatment of each component using guideline-directed pharmacotherapy, and longitudinal surveillance for downstream complications.

Diagnosis recap: ≥3 of 5 ATP III criteria — waist (≥102/88 cm, lower for Asians), TG ≥150, HDL <40/<50, BP ≥130/85, FPG ≥100; no single criterion mandatory, and the construct identifies a high-risk patient rather than a discrete disease.

First-line treatment recap: Mediterranean/DASH diet, 150 min/week moderate aerobic + 2 resistance sessions, 7–10% weight loss (DPP: 58% T2DM reduction, beating metformin's 31%), tobacco cessation, OSA treatment, and treatment of each metabolic component to guideline targets (ACEi/ARB for HTN with microalbuminuria, moderate-to-high intensity statin per ASCVD risk, metformin for high-risk prediabetes, GLP-1 RA/SGLT2i once T2DM established with ASCVD/HF/CKD).

High-yield safety recap: Avoid high-dose thiazides and non-vasodilating β-blockers as first-line in metabolic syndrome (worsen insulin resistance); deprescribe sulfonylureas/insulin/antihypertensives post-bariatric surgery to prevent hypoglycemia and orthostasis; do not start aspirin for primary prevention in adults ≥60; screen postpartum GDM patients with 75-g OGTT at 4–12 weeks and annually thereafter.

Differential recap: Always consider and screen for secondary contributors before escalating polypharmacy — Cushing syndrome, hypothyroidism, primary aldosteronism (especially with hypokalemia), acromegaly, PCOS, drug-induced (atypical antipsychotics, glucocorticoids, integrase inhibitors), and lipodystrophies — and address NAFLD with FIB-4 staging and OSA with sleep study because treating the driver outperforms treating each downstream lab.

Board pearl: When in doubt on a Step 3 stem about an asymptomatic metabolic syndrome patient — document shared decision-making, prescribe structured lifestyle intervention with a dietitian referral, and schedule close follow-up before adding new pharmacotherapy; when established cardiovascular disease or diabetes is present, deliver the full guideline-directed bundle with cardiac rehab and secondary prevention medications.